Adverse Events and Treatment Tolerability of Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: A Real World Study

Background: Antifibrotic therapies slow disease progression in idiopathic pulmonary fibrosis (IPF) and are increasingly used in progressive pulmonary fibrosis (PPF), but adverse events may compromise treatment persistence. This study evaluated adverse events and treatment tolerability with pirfenidone and nintedanib in patients with IPF or PPF. Methods: This single-center ambidirectional study included 151 patients treated from January 2022 to June 2025 (120 retrospective; 31 prospective). Adverse events and treatment modifications were recorded. Results: Mean age was 67.5 ± 10.1 years; 64.9% were male, 68.9% had IPF, and 31.1% had PPF. At least one adverse event occurred in 56.3%, most commonly nausea (32.5%), vomiting (21.9%), and diarrhea (17.9%). Overall adverse-event rates were similar with pirfenidone and nintedanib (52.4% vs. 61.2%; p = 0.278). Diarrhea (6.0% vs. 32.8%; p < 0.001) and vomiting (15.5% vs. 29.9%; p = 0.034) were more frequent with nintedanib, whereas photosensitivity was more frequent with pirfenidone (16.7% vs. 1.5%; p = 0.002). Diabetes mellitus was associated with adverse events (74.1% vs. 52.4%; p = 0.040). Permanent treatment discontinuation occurred in 7.9%. Conclusions: Adverse events were common but generally manageable. The agents showed distinct adverse-event profiles, supporting early, individualized monitoring to acilitate treatment continuation.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-12
DOI
https://doi.org/10.20944/preprints202611.1300.v1
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Adverse Events and Treatment Tolerability of Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: A Real World Study

Talat Kılıç, Yunus Emre Er
Preprints.org
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
preprint

Adverse Events and Treatment Tolerability of Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: A Real World Study

Talat Kılıç, Yunus Emre Er
preprint en

Abstract

Background: Antifibrotic therapies slow disease progression in idiopathic pulmonary fibrosis (IPF) and are increasingly used in progressive pulmonary fibrosis (PPF), but adverse events may compromise treatment persistence. This study evaluated adverse events and treatment tolerability with pirfenidone and nintedanib in patients with IPF or PPF. Methods: This single-center ambidirectional study included 151 patients treated from January 2022 to June 2025 (120 retrospective; 31 prospective). Adverse events and treatment modifications were recorded. Results: Mean age was 67.5 ± 10.1 years; 64.9% were male, 68.9% had IPF, and 31.1% had PPF. At least one adverse event occurred in 56.3%, most commonly nausea (32.5%), vomiting (21.9%), and diarrhea (17.9%). Overall adverse-event rates were similar with pirfenidone and nintedanib (52.4% vs. 61.2%; p = 0.278). Diarrhea (6.0% vs. 32.8%; p < 0.001) and vomiting (15.5% vs. 29.9%; p = 0.034) were more frequent with nintedanib, whereas photosensitivity was more frequent with pirfenidone (16.7% vs. 1.5%; p = 0.002). Diabetes mellitus was associated with adverse events (74.1% vs. 52.4%; p = 0.040). Permanent treatment discontinuation occurred in 7.9%. Conclusions: Adverse events were common but generally manageable. The agents showed distinct adverse-event profiles, supporting early, individualized monitoring to acilitate treatment continuation.

Preprints.org
Good health and well-being
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon